Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
25 hedge funds and large institutions have $3.25M invested in Aptose Biosciences, Inc. in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0% more capital invested
Capital invested by funds: $3.25M → $3.25M (+$3.88K)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$341K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$115K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$40K |
| 4 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$32.2K |
| 5 |
CA
Cetera Advisors
Denver,
Colorado
|
+$24.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$182K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$42.3K |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
-$25.9K |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$12.9K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$4.27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
National Bank of Canada
Montreal,
Quebec, Canada
| $33 | – | – | – |
|
|
PCWA
27
Pacific Capital Wealth Advisors
Corona,
California
| $15 | – | – | – |
|
28
Citigroup
New York
| $3 | – | – | – |
|
29
Fidelity International
Hamilton,
Bermuda
| $3 | – | – | – |
|
|
30
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$12.9K | -153 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$526 | -6 | Closed |
|
APTO Hedge Fund Activity: Q4 2023 in Review
25 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q4 2023, worth a combined $3.25M — up 0.12% from $3.25M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new APTO positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $341K. The largest seller was Sigma Planning Corp, cutting an estimated $182K.
- 25 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $3.25M of Aptose Biosciences, Inc. stock for Q4 2023, up 0.12% quarter-over-quarter.
- 3 funds opened new Aptose Biosciences, Inc. positions in Q4 2023 and 2 closed out, a net change of +1 holder.
- The largest Aptose Biosciences, Inc. buyer in Q4 2023 was Morgan Stanley, an estimated $341K added.
- The largest Aptose Biosciences, Inc. seller in Q4 2023 was Sigma Planning Corp, an estimated $182K sold.
Based on aggregated 13F filings for Q4 2023.